[Italian guidelines for the diagnosis and treatment of Paget's disease of bone].
暂无分享,去创建一个
S. Adami | R. Nuti | S. Gonnelli | A. Falchetti | G. Isaia | M. Brandi | P. Filipponi | G. Bianchi | P. Bartolozzi | Gc Isaia
[1] Pasquale Strazzullo,et al. Evidence for Increased Clinical Severity of Familial and Sporadic Paget's Disease of Bone in Campania, Southern Italy , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] Jacques P. Brown,et al. Long‐Term Control of Bone Turnover in Paget's Disease With Zoledronic Acid and Risedronate , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] J. Walsh,et al. A Novel Mutation (K378X) in the Sequestosome 1 Gene Associated With Increased NF‐κB Signaling and Paget's Disease of Bone With a Severe Phenotype , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] G. H. Nancollas,et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. , 2006, Bone.
[5] R. Nuti,et al. Prevalence of Paget's Disease of Bone in Italy , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] Jacques P. Brown,et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. , 2005, The New England journal of medicine.
[7] R. Nuti,et al. Characteristics and Familial Aggregation of Paget's Disease of Bone in Italy , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[8] M. Brandi,et al. Two Novel Mutations at Exon 8 of the Sequestosome 1 (SQSTM1) Gene in an Italian Series of Patients Affected by Paget's Disease of Bone (PDB) , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[9] C. Cooper,et al. Incidence and Natural History of Paget's Disease of Bone in England and Wales , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[10] W. O'Fallon,et al. Fracture Risk Among Patients with Paget's Disease: A Population‐Based Cohort Study , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[11] C. Hayes,et al. Improvement of pagetic bone lesions with risedronate treatment: a radiologic study. , 2000, Bone.
[12] M. Porter,et al. Charnley low-friction arthroplasty for Paget's disease of the hip. , 2000, The Journal of arthroplasty.
[13] C. Mautalen,et al. Short‐Term Therapy with Oral Olpadronate in Active Paget's Disease of Bone , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[14] S. Vasikaran,et al. Paget's disease: Acquired resistance to one aminobisphosphonate with retained response to another , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[15] P. Selby. Pamidronate in the treatment of Paget's disease. , 1999, Bone.
[16] A. Grauer,et al. Ibandronate treatment in Paget's disease of bone. , 1999, Bone.
[17] Jacques P. Brown,et al. A randomized, double-blind comparison of risedronate and etidronate in the treatment of paget’s disease of bone , 1999 .
[18] J. Reginster,et al. Risedronate, a Highly Effective, Short-Term Oral Treatment for Paget's Disease: A Dose-Response Study , 1999, Calcified Tissue International.
[19] E. Dennison,et al. The Epidemiology of Paget's Disease in Britain: Is the Prevalence Decreasing? , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[20] P. Filipponi,et al. Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate. , 1998, Bone.
[21] S. Ralston,et al. Genetics of Paget's disease of bone. , 1998, Clinical science.
[22] Jacques P. Brown,et al. Risedronate in the Treatment of Paget's Disease of Bone: An Open Label, Multicenter Study , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[23] P. Delmas,et al. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. , 1998, Arthritis and rheumatism.
[24] W. Fraser,et al. A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone. , 1997, Postgraduate medical journal.
[25] E. Siris,et al. Antiresorptive Effect of a Single Infusion of Microgram Quantities of Zoledronate in Paget's Disease of Bone , 1997, Calcified Tissue International.
[26] J. Kanis,et al. Alendronate in the treatment of Paget's disease of bone. , 1997, Bone.
[27] D. Gold,et al. Paget's disease of bone and quality of life , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[28] W. Murphy,et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. , 1996, The American journal of medicine.
[29] W. Murphy,et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. , 1996, The Journal of clinical endocrinology and metabolism.
[30] G. Fabry,et al. The Ilizarov External Fixator for Treatment of Deformities in Paget's Disease , 1996, Clinical orthopaedics and related research.
[31] I. Reid,et al. Pamidronate treatment of the neurologic sequelae of pagetic spinal stenosis. , 1995, Archives of internal medicine.
[32] N. P. O’Donnell,et al. PAGET'S DISEASE: OCULAR COMPLICATIONS OF DISODIUM PAMIDRONATE TREATMENT , 1995, The British journal of clinical practice.
[33] M. Dougados,et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. , 1995, Arthritis and rheumatism.
[34] R. Deulofeu,et al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[35] F. Fraunfelder,et al. Pamidronate disodium and possible ocular adverse drug reactions. , 1994, American journal of ophthalmology.
[36] S. Adami,et al. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. , 1994, Bone.
[37] J. Highton,et al. Uveitis associated with pamidronate. , 1994, Australian and New Zealand journal of medicine.
[38] P. Filipponi,et al. Effects of two different bisphosphonates on Paget's disease of bone: ICTP assessed. , 1994, Bone.
[39] S. Adami,et al. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. , 1994, Bone and mineral.
[40] R. Watts,et al. Treatment of Paget's disease of bone with single dose intravenous pamidronate. , 1994, Annals of the Rheumatic Diseases.
[41] S. Ralston,et al. Mineralisation defects with pamidronate therapy for Paget's disease , 1993, The Lancet.
[42] A. Zwinderman,et al. Improved treatment of paget's disease with dimethylaminohydroxypropylidene bisphosphonate , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[43] I. Fogelman,et al. Bone scintigraphy following intravenous pamidronate for Paget's disease of bone. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[44] P. Geusens,et al. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study. , 1992, Arthritis and rheumatism.
[45] I. Fogelman,et al. Treatment of Paget's disease by weekly infusions of 3-aminohydroxypropylidene-1,1-bisphosphonate (APD). , 1992, British journal of rheumatology.
[46] R. Price,et al. Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric and radiological responses , 1991, Clinical endocrinology.
[47] D. Hosking,et al. Treatment of paget's disease with intermittent low‐dose infusions of disodium pamidronate (APD) , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[48] J. Mckillop,et al. Serial bone scans in Paget's disease: Development of new lesions, natural variation in lesion intensity and nature of changes seen after treatment , 1990, Nuclear medicine communications.
[49] J. Kanis,et al. Treatment of paget's disease of bone with aminohydroxybutylidene bisphosphonate , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[50] Sandy Bidner,et al. Femoral Fractures in Paget's Disease , 1989, Journal of orthopaedic trauma.
[51] L. Mallette. Successful treatment of resistant Paget's disease of bone with pamidronate. , 1989, Archives of internal medicine.
[52] C. Löwik,et al. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[53] M. Audran,et al. Treatment of Paget's disease of bone with (4-chloro-phenyl) thiomethylene bisphosphonate , 1989, Clinical Rheumatology.
[54] D. Anderson,et al. Relapse of osteoporosis circumscripta as a lytic ring after treatment of Paget's disease with intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate. , 1988, The British journal of radiology.
[55] C. Gobelet,et al. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone. , 1988, The American journal of medicine.
[56] D. Anderson,et al. Paget's disease of the orbit: before and after APD. , 1987, British medical journal.
[57] S. Adami,et al. The acute-phase response after bisphosphonate administration , 1987, Calcified Tissue International.
[58] S. Papapoulos,et al. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). , 1987, British medical journal.
[59] J. Kanis,et al. Duration of effect of oral diphosphonate therapy in Paget's disease of bone. , 1987, The Quarterly journal of medicine.
[60] D. Wattie,et al. Radiological assessment of Paget's disease of bone after treatment with the bisphosphonates EHDP and APD. , 1987, The British journal of radiology.
[61] C. Mautalen,et al. Intravenous aminopropylidene bisphosphonate (APD) in the treatment of paget's bone disease , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[62] P. Delmas,et al. Skeletal distribution and biochemical parameters of Paget's disease. , 1987, Clinical orthopaedics and related research.
[63] D. Thiebaud,et al. Paget's disease of bone treated in five days with AHPrBP (APD) per Os , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[64] M. Zaaroor,et al. Spinal cord compression in Paget's disease of bone with reference to sarcomatous degeneration and calcitonin treatment. , 1987, Surgical neurology.
[65] S. Ralston,et al. The effect of 1α‐hydroxyvitamin D3 on the mineralization defect in disodium etidronate‐treated paget's disease — a double‐blind randomized clinical study , 1987 .
[66] D. Anderson,et al. Lowdoseintravenous 3-amino-i- hydroxypropylide ne-1,1-bisphosph onate (APD)for thetreatment ofPaget's disease ofbone , 1986 .
[67] S. Adami,et al. Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate , 1986, Calcified Tissue International.
[68] M. Peacock,et al. Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate. , 1986, British medical journal.
[69] E. Pauwels,et al. Quantitative bone scintigraphy in Paget's disease treated with APD. , 1985, The British journal of radiology.
[70] R. Altman. Long-term follow-up of therapy with intermittent etidronate disodium in Paget's disease of bone. , 1985, The American journal of medicine.
[71] J. Kanis,et al. INTRAVENOUS CLODRONATE IN THE TREATMENT AND RETREATMENT OF PAGET'S DISEASE OF BONE , 1985, The Lancet.
[72] J. Kanis,et al. Carcinoma of the prostate: remission of paraparesis with inhibitors of bone resorption. , 1985, Postgraduate medical journal.
[73] B. K. Prasad,et al. Clinical experience with the use of two diphosphonates in the treatment of Paget's disease. , 1985, Annals of the rheumatic diseases.
[74] S. Ralston,et al. FOCAL OSTEOMALACIA DUE TO LOW-DOSE DIPHOSPHONATE THERAPY IN PAGET'S DISEASE , 1984, The Lancet.
[75] M. Passeri,et al. SIDE-EFFECTS OF SYNTHETIC SALMON AND HUMAN CALCITONIN , 1983, The Lancet.
[76] G. Weisz. Lumbar Spinal Canal Stenosis in Paget's Disease , 1983, Spine.
[77] M. Chapuy,et al. INTRAVENOUS ETIDRONATE FOR SPINAL CORD DYSFUNCTION DUE TO PAGET'S DISEASE , 1982, The Lancet.
[78] J. Kanis,et al. Spinal cord dysfunction in Paget's disease of bone. Has medical treatment a vascular basis? , 1981, The Journal of bone and joint surgery. British volume.
[79] J. Kanis,et al. Biochemical and clinical responses to dichloromethylene diphosphonate (Cl2MDP) in Paget's disease of bone. , 1980, Arthritis and rheumatism.
[80] L.,et al. TREATMENT OF PAGET'S DISEASE WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.) , 1979, The Lancet.
[81] S. Wallach,et al. Neurologic disturbances in Paget disease of bone , 1979, Neurology.
[82] I. Chalmers,et al. Long term effectiveness of low dose mithramycin for Paget's disease of bone. , 1979, Arthritis and rheumatism.
[83] R. Altman,et al. Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results. , 1977, Annals of internal medicine.
[84] M. Schumacher,et al. Paget’s Disease with Spinal Cord Compression , 1977 .
[85] M. Gardner,et al. Paget's disease of bone in 14 British towns. , 1977, British medical journal.
[86] S. Bowring,et al. A comparison of radiography and radioisotope scanning in the detection of Paget's disease and in the assessment of response to human calcitonin. , 1977, The British journal of radiology.
[87] J. A. Strong,et al. Treatment of Paget's disease of bone with porcine calcitonin: clinical and metabolic responses. , 1975, The Quarterly journal of medicine.
[88] H. Wellman,et al. Radiographs and scans in diagnosing symptomatic lesions of Paget's disease of bone (osteitis deformans). , 1974, Geriatrics.
[89] R. Altman,et al. Treatment of Paget disease of bone (osteitis deformans). Results of a one-year study with sodium etidronate. , 1974, JAMA.
[90] R. Russell,et al. Diphosphonates in Paget's disease. , 1974, Lancet.
[91] R. Altman,et al. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). , 1973, The New England journal of medicine.
[92] W. Ryan. Mithramycin in Paget's disease of bone. , 1973, Lancet.
[93] R. Lindsay,et al. Mithramycin in Paget's disease. , 1973, Lancet.
[94] J. Evans,et al. Mithramycin in the treatment of Paget's disease of bone. , 1972, The Journal of bone and joint surgery. American volume.
[95] S. Wallach,et al. The clinical and metabolic effects of porcine calcitonin on Paget's disease of bone. , 1971, The Journal of clinical investigation.
[96] Steinbach Hl. Some roentgen features of Paget's disease. , 1961 .
[97] F. Sim,et al. Paget’s disease of the hip , 2004 .
[98] S. Ortolani,et al. Short-term intravenous therapy with Neridronate in Paget's disease. , 2002, Clinical and experimental rheumatology.
[99] E. Siris,et al. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. , 1999, The American journal of medicine.
[100] G. Gamble,et al. Evidence for secular change in Paget's disease. , 1997, Bone.
[101] C. Mautalen,et al. Preliminary study of multiple increasing oral doses of dimethyl-APD on bone metabolism dynamics and safety profile. , 1994, Drugs under experimental and clinical research.
[102] S. Nade,et al. Outcome after fractures of the femur in Paget's disease. , 1992, The Australian and New Zealand journal of surgery.
[103] R. Mortimer,et al. Single-dose intravenous pamidronate is effective alternative therapy for Paget's disease refractory to calcitonin. , 1991, Hormone research.
[104] P. Burke,et al. Improvement in the deformity of the face in Paget's disease treated with diphosphonates. , 1990, The Journal of bone and joint surgery. British volume.
[105] J. Reginster,et al. Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone. , 1988, Bone.
[106] S. Ralston,et al. The effect of 1 alpha-hydroxyvitamin D3 on the mineralization defect in disodium etidronate-treated Paget's disease--a double-blind randomized clinical study. , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[107] C. Mautalen,et al. Efficacy of the bisphosphonate APD in the control of Paget's bone disease. , 1985, Bone.
[108] S. Adami,et al. Sequential treatment of Paget's disease with human calcitonin and dichloromethylene diphosphonate (Cl2MDP). , 1984, Metabolic bone disease & related research.
[109] E. Siris,et al. Clinical and biochemical effects of EHDP in Paget's disease of bone: patterns of response to initial treatment and to long-term therapy. , 1981, Metabolic bone disease & related research.
[110] D. Heath. The role of mithramycin in the management of Paget's disease. , 1981, Metabolic bone disease & related research.
[111] R. Canfield,et al. Diphosphonate therapy of paget's disease of bone. , 1977, The Journal of clinical endocrinology and metabolism.
[112] M. Schumacher,et al. Paget's disease with spinal cord compression. Favourable course after decompression and calcitonin treatment in two cases. , 1977, European neurology.
[113] H. Wellman,et al. Skeletal scintimaging and radiography in the diagnosis and management of Paget's disease. , 1977, Clinical orthopaedics and related research.
[114] P. Greenberg,et al. Otological studies in patients with deafness due to Paget's disease before and after treatment with synthetic human calcitonin. , 1975, Acta oto-laryngologica.
[115] R. Sherman,et al. Roentgen diagnosis of Paget's disease (Osteitis deformans). The usual, the unusual, and the complications. , 1970, Dental radiography and photography.
[116] H. Steinbach. Some roentgen features of Paget's disease. , 1961, The American journal of roentgenology, radium therapy, and nuclear medicine.